The pharmacology of selegiline

Research output: Chapter in Book/Report/Conference proceedingChapter

41 Citations (Scopus)

Abstract

Selegiline, the R-optical enantiomer of deprenyl (phenyl-isopropyl-methyl-propargylamine), was almost exclusively used MAO-B inhibitor during the past decades to treat Parkinson's disease. Oral treatment prolongs the need of levodopa administration. Selegiline is rapidly metabolized by the microsomal enzymes to amphetamine, methamphetamine, and desmethyl-deprenyl. In addition, the flavin-containing monooxigenase is synthesizing deprenyl-N-oxide. Selegiline in rather low concentrations (10 -9 -10 -13 M), does not influence MAO-B, but it has an antiapoptotic activity in tissue culture. The neuroprotective effect of selegiline has a biphasic character. In higher concentrations than 10 -7 M increases the rate of apoptosis (proapoptotic activity). The metabolites are also taking part in the complex pharmacological activity of selegiline. The simultaneous presence of the pro- and antiapoptotic effects of selegiline and its metabolites frequently hindered its clinical usage. During the past years rasagiline has been introduced to replace selegiline in clinical application. MAO-B inhibitors beside their effect on the enzyme MAO-B could hold different spectrum of pharmacological activities. Selegiline is administered orally and it possesses an intensive "first pass" metabolism. To circumvent the "first pass" metabolism, parenteral administration of the drug might lead to different distribution and pharmacological activity of selegiline.

Original languageEnglish
Title of host publicationInternational Review of Neurobiology
PublisherAcademic Press Inc.
Pages65-84
Number of pages20
DOIs
Publication statusPublished - 2011

Publication series

NameInternational Review of Neurobiology
Volume100
ISSN (Print)0074-7742

Keywords

  • Antiapoptotic effect of selegiline
  • Future perspectives of selegiline
  • Metabolic studies
  • Multiplicity of monoamine oxidase
  • Pharmacokinetics
  • Selective inhibition of MAO-B
  • Structure-activity relationship studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'The pharmacology of selegiline'. Together they form a unique fingerprint.

  • Cite this

    Magyar, K. (2011). The pharmacology of selegiline. In International Review of Neurobiology (pp. 65-84). (International Review of Neurobiology; Vol. 100). Academic Press Inc.. https://doi.org/10.1016/B978-0-12-386467-3.00004-2